$303 Million is the total value of RTW INVESTMENTS, LP's 29 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | Berkshire Hathaway Inccl b new | $0 | – | -50 | -100.0% | -0.00% | – | |
| VCYT | Exit | Veracyte Inc | $0 | – | -25,000 | -100.0% | -0.04% | – |
| ELGX | Exit | Endologix Inc | $0 | – | -15,000 | -100.0% | -0.06% | – |
| GHDX | Exit | Genomic Health Inc | $0 | – | -15,000 | -100.0% | -0.10% | – |
| NTRA | Exit | Natera Inc | $0 | – | -31,693 | -100.0% | -0.11% | – |
| BCRX | Exit | BCRX 12/18/2015 CALL 12call | $0 | – | -2,000 | -100.0% | -0.13% | – |
| MDRX | Exit | Allscripts Healthcare Solutions Inc | $0 | – | -48,000 | -100.0% | -0.18% | – |
| MASI | Exit | Masimo Corp | $0 | – | -25,900 | -100.0% | -0.31% | – |
| NLNK | Exit | NewLink Genetics Corp | $0 | – | -28,291 | -100.0% | -0.32% | – |
| OSUR | Exit | OraSure Technologies Inc | $0 | – | -322,996 | -100.0% | -0.45% | – |
| VBIV | Exit | Vbi Vaccines Inc | $0 | – | -650,000 | -100.0% | -0.53% | – |
| RPRX | Exit | Repros Therapeutics Inc | $0 | – | -232,830 | -100.0% | -0.54% | – |
| CBIO | Exit | Catalyst Biosciences Inc | $0 | – | -380,806 | -100.0% | -0.55% | – |
| LENS | Exit | Presbia Plc | $0 | – | -350,000 | -100.0% | -0.60% | – |
| BMY | Exit | BMY 01/15/2016 CALL 60call | $0 | – | -7,500 | -100.0% | -0.80% | – |
| Exit | Atara Biotherapeutics Inc. | $0 | – | -262,995 | -100.0% | -2.57% | – | |
| Exit | Arrowhead Research Corp | $0 | – | -2,097,185 | -100.0% | -3.75% | – | |
| BLUE | Exit | bluebird bio Inc | $0 | – | -151,594 | -100.0% | -4.03% | – |
| INCY | Exit | Incyte Corp | $0 | – | -303,212 | -100.0% | -10.39% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.